Current studentsExisting staffContact us
 

The Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data

Simple item page
dc.contributor.authorModi, N.D.
dc.contributor.authorTan, J.Q.E.
dc.contributor.authorRowland, A.
dc.contributor.authorKoczwara, B.
dc.contributor.authorKichenadasse, G.
dc.contributor.authorMcKinnon, R.A.
dc.contributor.authorWiese, M.D.
dc.contributor.authorSorich, M.J.
dc.contributor.authorHopkins, A.M.
dc.date.issued2020
dc.descriptionData source: Supplementary material, https://www.frontiersin.org/articles/10.3389/fonc.2020.01130/full#supplementary-material Link to a related website: https://www.frontiersin.org/articles/10.3389/fonc.2020.01130/pdf, Open Access via Unpaywall
dc.description.abstract<b>Introduction:</b> Beta-blockers (BB) are commonly used to manage cardiovascular disease and may have benefits in controlling complications of anti-HER2 therapies. This study aimed to evaluate the association of pre-existing BB use with survival outcomes in patients initiating anti-HER2 therapy for advanced breast cancer (ABC). <b>Materials and Methods:</b> Data from clinical trials EMILIA, TH3RESA, MARIANNE, and CLEOPATRA was pooled. Cox proportional analysis was used to assess the association between pre-existing BB use with survival outcomes in patients initiating anti-HER2 therapies. <b>Results:</b> Of the 2,777 patients with HER2 positive ABC, 266 were using a BB at the time of anti-HER2 therapy initiation. BB use was associated with worse overall survival (OS) (adjusted HR = 1.27, 95% CI: 1.04-1.55). Sensitivity analysis in patients with pre-existing cardiovascular disease (CVD) also indicated that BB use was associated with worse OS (1.29, 1.02-1.63). <b>Conclusion:</b> In large high-quality data, BB use at the time of anti-HER2 therapy initiation for ABC was independently associated with worse OS, regardless of CVD status. The finding is contrary to pre-study hypotheses and findings in other BC subtypes. Future research should aim to gain a deeper understanding of the effects of BBs on specific BC subtypes, cancer types, and cancer treatments.
dc.identifier.citationFrontiers in Oncology, 2020; 10(1130):1130-
dc.identifier.doi10.3389/fonc.2020.01130
dc.identifier.issn2234-943X
dc.identifier.issn2234-943X
dc.identifier.orcidModi, N.D. [0000-0003-3262-5374]
dc.identifier.urihttps://hdl.handle.net/11541.2/146299
dc.language.isoen
dc.publisherFrontiers Media SA
dc.rightsCopyright 2020 Frontiers Research Foundation
dc.source.urihttps://doi.org/10.3389/fonc.2020.01130
dc.subjectHER2 positive
dc.subjectbeta-blockers
dc.subjectbreast cancer
dc.subjectsurvival
dc.subjecttargeted therapy
dc.titleThe Influence of Pre-Existing Beta-Blockers Use on Survival Outcomes in HER2 Positive Advanced Breast Cancer: Pooled Analysis of Clinical Trial Data
dc.typeJournal article
pubs.publication-statusPublished
ror.mmsid9916433899701831

Files

Collections